Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDAVP Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in Cushing's Disease
NCT04569591Recruiting
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Mar 2026
- Primary completion
- Feb 2028
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of desmopressin in Cushing's disease (CD) and pituitary adenoma, sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoint: Detection of tumor in MRI-negative cases by DDAVP-stimulated PET imaging. Started Mar 2026; status: recruiting.
02
Drugs
desmopressin
03
Conditions
Cushing's disease (CD)pituitary adenoma
Beyond the preview
Go deeper on NCT04569591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04569591.